These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25123843)

  • 1. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy.
    Corcoran AT; Kaffenberger SD; Clark PE; Walton J; Handorf E; Piotrowski Z; Tomaszewski JJ; Ginzburg S; Mehrazin R; Plimack E; Chen DY; Smaldone MC; Uzzo RG; Morgan TM; Kutikov A
    BJU Int; 2015 Sep; 116(3):351-7. PubMed ID: 25123843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
    Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of nutritional deficiency on prognosis of renal cell carcinoma (RCC).
    Ko K; Park YH; Lee JW; Ku JH; Kwak C; Kim HH
    BJU Int; 2013 Oct; 112(6):775-80. PubMed ID: 24028765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
    Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
    Culp SH; Karam JA; Wood CG
    Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.
    Morgan TM; Tang D; Stratton KL; Barocas DA; Anderson CB; Gregg JR; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
    Eur Urol; 2011 Jun; 59(6):923-8. PubMed ID: 21295907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
    Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
    Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
    Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
    Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
    Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.
    Spiess PE; Kurian T; Lin HY; Rawal B; Kim T; Sexton WJ; Pow-Sang JM
    BJU Int; 2012 Dec; 110(11 Pt B):E470-4. PubMed ID: 22519938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
    Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
    Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
    Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
    Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.